At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SAVA Cassava Sciences Inc
Trading 02-24 15:18:01 EST
2.46
+0.30
+13.89%
High2.47Low2.14Vol1.87M
Open2.17D1 Closing2.16Amplitude15.27%
Mkt Cap118.84MTradable Cap106.95MTotal Shares48.31M
T/O4.43MT/O Rate4.30%Tradable Shares43.48M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Ensysce Biosciences Executives to Present at USASP Annual Scientific Meeting
Reuters  ·  02-23 21:01
Ensysce Biosciences Executives to Present at USASP Annual Scientific Meeting
Cassava Sciences DOJ Inquiry Closed, Legal Overhang Eased
TIPRANKS  ·  02-19
Cassava Sciences DOJ Inquiry Closed, Legal Overhang Eased
BUZZ-Cassava Sciences rises after US DOJ closes probe into company
Reuters  ·  02-19
BUZZ-Cassava Sciences rises after US DOJ closes probe into company
Cassava Sciences Says DOJ Closes Investigation
Reuters  ·  02-19
Cassava Sciences Says DOJ Closes Investigation
Cassava Sciences Inc - Indictment Dismissed With Prejudice by DOJ
THOMSON REUTERS  ·  02-19
Cassava Sciences Inc - Indictment Dismissed With Prejudice by DOJ
Cassava Announces Closure of U.S. Department of Justice Investigation
GlobeNewswire  ·  02-19
Cassava Announces Closure of U.S. Department of Justice Investigation
Cassava Sciences And 2 Other Promising Penny Stocks
Simply Wall St.  ·  02-12
Cassava Sciences And 2 Other Promising Penny Stocks
Cassava Sciences announces publication of Phase 3 results for simufilam
TIPRANKS  ·  01-13
Cassava Sciences announces publication of Phase 3 results for simufilam
Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease
GlobeNewswire  ·  01-13
Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease
SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects
GlobeNewswire  ·  2025-12-30
SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects
Cassava Sciences Inc: Will Pay $31.25 Mln for Complete Settlement and Release of All Claims
THOMSON REUTERS  ·  2025-12-23
Cassava Sciences Inc: Will Pay $31.25 Mln for Complete Settlement and Release of All Claims
Cassava Sciences: to Resolve Litigation Filed in US District Court in Texas
THOMSON REUTERS  ·  2025-12-23
Cassava Sciences: to Resolve Litigation Filed in US District Court in Texas
Cassava Sciences Settles Securities Class Action for $31.25 Million
Reuters  ·  2025-12-23
Cassava Sciences Settles Securities Class Action for $31.25 Million
Cassava Announces Agreement to Settle Securities Class Action Litigation
GlobeNewswire  ·  2025-12-23
Cassava Announces Agreement to Settle Securities Class Action Litigation
Cassava Sciences Names Dawn C. Bir to Compensation Committee
Reuters  ·  2025-12-23
Cassava Sciences Names Dawn C. Bir to Compensation Committee
Correction: Investors Hope for Rate Cut Following Subdued Inflation as US Futures Mixed in Friday's Premarket Session
MT Newswires Live  ·  2025-12-19
Correction: Investors Hope for Rate Cut Following Subdued Inflation as US Futures Mixed in Friday's Premarket Session
Stocks to Watch: Nike, Cassava Sciences, KB Home
Dow Jones  ·  2025-12-19
Stocks to Watch: Nike, Cassava Sciences, KB Home
Cassava Sciences Inc - on Dec 15, FDA Places Full Clinical Hold on Cassava's Trial - SEC Filing
THOMSON REUTERS  ·  2025-12-19
Cassava Sciences Inc - on Dec 15, FDA Places Full Clinical Hold on Cassava's Trial - SEC Filing
Cassava Sciences: Not Expected to Initiate Proof-of-Concept Clinical Trial for Simufilam in Tsc-Related Epilepsy in H1 2026 as Previously Disclosed
THOMSON REUTERS  ·  2025-12-19
Cassava Sciences: Not Expected to Initiate Proof-of-Concept Clinical Trial for Simufilam in Tsc-Related Epilepsy in H1 2026 as Previously Disclosed
FDA Puts Cassava Sciences Simufilam Trial on Full Clinical Hold
Reuters  ·  2025-12-19
FDA Puts Cassava Sciences Simufilam Trial on Full Clinical Hold

Introduction

Company Name.
Cassava Sciences Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
Issue price:
--